RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · Real-Time Price · USD
1.285
-0.055 (-4.10%)
At close: Jul 11, 2025, 4:00 PM
1.290
+0.005 (0.39%)
After-hours: Jul 11, 2025, 7:08 PM EDT
RenovoRx Employees
RenovoRx had 10 employees as of December 31, 2024. The number of employees increased by 2 or 25.00% compared to the previous year.
Employees
10
Change (1Y)
2
Growth (1Y)
25.00%
Revenue / Employee
$24,000
Profits / Employee
-$1,015,800
Market Cap
47.00M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10 | 2 | 25.00% |
| Dec 31, 2023 | 8 | -1 | -11.11% |
| Dec 31, 2022 | 9 | 3 | 50.00% |
| Dec 31, 2021 | 6 | -3 | -33.33% |
| Dec 31, 2020 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RNXT News
- 2 months ago - RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha
- 2 months ago - RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights - Business Wire
- 2 months ago - RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st - Business Wire
- 2 months ago - U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform - Business Wire
- 2 months ago - RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET - Business Wire
- 2 months ago - Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial - Business Wire
- 3 months ago - RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community - Business Wire
- 3 months ago - RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th - Business Wire